MK0524 Asthma POC Study (0524-008)(COMPLETED)
Phase 2
Completed
- Conditions
- Asthma
- Registration Number
- NCT00783601
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The purpose of the study is to demonstrate the benefit of MK0524 compared to placebo in patients with chronic asthma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 130
Inclusion Criteria
- Has symptoms of chronic asthma (shortness of breath, wheezing, chest tightness, etc.) for at least 1 year
- Nonsmoker for at least 1 year with a smoking history of no more than 7 pack-years (i.e., 1 pack per day for 7 years)
Read More
Exclusion Criteria
- Any clinically significant disease of heart, intestinal, kidney, liver, lung or uncontrolled blood pressure
- Any surgery within 4 weeks prior to Visit 1
- Patient is intending to move or vacation for more than 5 days during the study
- Patient is pregnant or breast-feeding
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method To demonstrate benefits of MK0524 compared with placebo on Forced Expiratory Volume in 1 second (FEV1) Last 2 weeks of each treatment period
- Secondary Outcome Measures
Name Time Method To determine the benefits of MK0524 as compared with placebo on the key secondary endpoints (Daytime & Nighttime Asthma Symptoms scores Last 2 weeks of each treatment period